FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Expansion of conventional dendritic cells via FMS-like tyrosine kinase 3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. In this study, we discuss the results of a clinical trial using GS-3583, an FMS-like tyrosine kinase 3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia. See related article by Tolcher et al., p. 2954.

Keyphrases

tyrosine kinase
epidermal growth factor receptor
acute myeloid leukemia
dendritic cells
clinical trial
immune response
randomized controlled trial
case report
regulatory t cells
double blind
drug induced